(Total Views: 482)
Posted On: 02/08/2021 1:46:44 PM
Post# of 153966
Market has a wait-and-see attitude about CYDY, and we all must do the same.
Biotech is flying today, but the market is waiting for Covid Phase III announcement and we are down/flat.
RLFTF announced they have been analyzing their phase III results and will present this month. They are up 26% on the announcement (also said starting Phase II inhaled form).
https://finance.yahoo.com/news/relief-affirms...00334.html
Am I dumb for not diversifying more now before results, or smart to wait for the (hopeful) runup afterwards?
If LL doesn't provide as big of a mortality benefit as hoped (at least 20%, but more likely 30%+ needed for quick approval?), at least we still have HIV, cancer, NASH, and the rest. It will just be a longer wait with more dilution.
$15 on success and $2 on failure?
Biotech is flying today, but the market is waiting for Covid Phase III announcement and we are down/flat.
RLFTF announced they have been analyzing their phase III results and will present this month. They are up 26% on the announcement (also said starting Phase II inhaled form).
https://finance.yahoo.com/news/relief-affirms...00334.html
Am I dumb for not diversifying more now before results, or smart to wait for the (hopeful) runup afterwards?
If LL doesn't provide as big of a mortality benefit as hoped (at least 20%, but more likely 30%+ needed for quick approval?), at least we still have HIV, cancer, NASH, and the rest. It will just be a longer wait with more dilution.
$15 on success and $2 on failure?
(1)
(0)
